Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine

https://ift.tt/K2QeMiF

from Sanofi - Aventis Groupe https://ift.tt/3ZEQn7G
via IFTTT

Post a Comment

0 Comments